Study to assess the efficacy and safety of Adjuvant Osimertinib in NSCLC with Uncommon EGFRm

Trial Identifier: D5161C00024
Sponsor: AstraZeneca
Start Date: February 2023
Primary Completion Date: June 2029
Study Completion Date: June 2029
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100730
CN Chengdu, CN, 610000
CN Chengdu, CN, 610041
CN fuzhou, CN, 350011
CN guangzhou, CN, 510080
CN Kunming, CN, 650118
CN Ningbo, CN, 315010
CN Shijiazhuang, CN, 050051
CN suzhou, CN, 215006
CN Tianjin, CN, 300060